Carcinoma of the Uterus
Find comprehensive information on Carcinoma of the Uterus, also known as Endometrial Cancer or Uterine Cancer. This resource offers guidance on diagnosis, ICD-10 coding (C54-C55), clinical documentation best practices, and healthcare management of Uterine Cancer. Learn about symptoms, staging, treatment options, and the latest research related to Carcinoma of the Uterus and Endometrial Cancer for accurate medical coding and improved patient care.
Cancer arising from the lining of the uterus (endometrium).
Abnormal vaginal bleeding, postmenopausal bleeding, pelvic pain.
Gynecology clinic, oncology center, primary care.
ICD-10 Code Families
Complete code families applicable to C55
When to use each related code
| Description | When to use |
|---|---|
| Malignant tumor of the uterine lining. | Use for malignancies arising from the endometrium. Code to specific histology when available. |
| Precancerous changes in the uterine lining. | Use for endometrial hyperplasia with atypia. A precursor to endometrial carcinoma. |
| Benign smooth muscle tumor of the uterus. | Use for uterine fibroids or leiomyomas. Distinguish from leiomyosarcomas. |
Best-practice checklist
- ✓Uterus carcinoma: Document stage, grade, and histology.
- ✓Endometrial cancer: Note tumor size, location, and myometrial invasion.
- ✓Uterine cancer: Specify if primary or recurrent.
- ✓Document any relevant imaging/lab results (e.g., MRI, CA-125).
- ✓Surgical details if applicable (e.g., hysterectomy type).
Common pitfalls to avoid
Unspecified histology may lead to incorrect C79.9 code assignment. CDI should clarify the specific type of uterine carcinoma for accurate coding.
Missing stage and grade information impacts accurate code assignment and reimbursement. CDI should query for complete staging and grading details.
Distinguishing primary uterine cancer from metastatic disease is crucial for accurate coding. CDI should confirm the primary site of the malignancy.
Best-practice tips
- 01Code C54.X for Uterine Carcinoma, specify histology.
- 02Document risk factors: age, obesity, HRT use.
- 03Stage precisely using FIGO staging system.
- 04Abstract comorbid conditions for accurate risk adjustment.
- 05Ensure timely follow-up documentation for compliance.
Step-by-step checklist
- 1
Verify ICD-10 C54.X, C55.X for uterine/endometrial cancer documentation accuracy.
- 2
Confirm histology report supports carcinoma diagnosis for patient safety.
- 3
Evaluate staging (FIGO) documented for proper treatment and coding.
- 4
Assess for relevant history, including abnormal bleeding, for risk factors.
Ready-to-paste narrative
Patient presents with complaints suggestive of uterine carcinoma, also known as endometrial cancer. Symptoms include abnormal uterine bleeding, postmenopausal bleeding, pelvic pain, and abnormal vaginal discharge. The patient's medical history includes [Insert relevant medical history, e.g., nulliparity, obesity, hypertension, diabetes, family history of endometrial cancer, use of tamoxifen, history of polycystic ovary syndrome]. Physical examination revealed [Insert findings, e.g., enlarged uterus, palpable pelvic mass, normal or abnormal cervical appearance]. A pelvic ultrasound was performed, demonstrating [Insert ultrasound findings, e.g., thickened endometrium, uterine mass]. Endometrial biopsy was performed, and histopathology confirmed the diagnosis of [Specify type, e.g., endometrioid adenocarcinoma, serous carcinoma] of the uterus. The diagnosis is consistent with ICD-10 code C54.9 (Malignant neoplasm of uterus, unspecified) and may be further specified based on histopathology. Staging workup, including imaging studies such as CT scan of the abdomen and pelvis and chest x-ray, is planned to determine the extent of the disease and guide treatment planning. Differential diagnoses considered included uterine fibroids, endometrial polyps, and atypical endometrial hyperplasia. The patient was counseled regarding treatment options, including surgery (hysterectomy, bilateral salpingo-oophorectomy), radiation therapy, chemotherapy, and hormone therapy. The risks and benefits of each treatment option were discussed, and the patient will be scheduled for consultation with a gynecologic oncologist for further management and treatment decisions. The patient understands the diagnosis and treatment plan. Follow-up appointments are scheduled for monitoring and ongoing care.
Common questions and answers
What are the most effective current staging guidelines for endometrial carcinoma for accurate prognosis and treatment planning?+
Accurate staging of endometrial carcinoma is crucial for prognosis and personalized treatment planning. The current gold standard is the 2009 FIGO staging system, which incorporates surgical assessment of myometrial invasion, cervical involvement, and regional and distant metastasis. While imaging modalities like MRI and PET/CT can be helpful preoperatively, surgical pathology remains definitive. Accurate staging also requires careful assessment of lymph node involvement, especially in higher-risk cases. Explore how advancements in molecular profiling are being integrated into staging to further refine risk stratification and guide treatment decisions.
How do I differentiate between Type I and Type II endometrial carcinoma in terms of histopathology, molecular profile, and clinical management implications?+
Differentiating Type I and Type II endometrial carcinomas is essential for tailored management. Type I, typically endometrioid histology, is often associated with estrogen excess, better prognosis, and is characterized by mutations in PTEN, CTNNB1, and KRAS. Type II, including serous, clear cell, and carcinosarcoma, tends to be more aggressive, is less hormone-sensitive, and harbors TP53 mutations, often with worse prognosis. These distinct molecular profiles are informing targeted therapies. Consider implementing molecular testing into your diagnostic workup to guide treatment choices and improve patient outcomes. Learn more about the role of specific molecular markers in personalizing treatment for endometrial carcinoma.
What are the best practices for post-operative surveillance and follow-up for patients with endometrial carcinoma, considering recurrence risk and patient-specific factors?+
Post-operative surveillance for endometrial carcinoma aims to detect recurrence early and manage long-term complications. The frequency and intensity of follow-up should be individualized based on stage, grade, histologic subtype, and patient-specific risk factors. Generally, history, physical examination, and CA-125 monitoring are recommended at regular intervals, while imaging studies like CT or MRI may be indicated based on individual risk stratification. Understanding the patterns and risk factors for recurrence is crucial for informed follow-up care. Explore how current research is refining personalized surveillance strategies to balance early detection with minimizing unnecessary interventions for patients with endometrial carcinoma.
Clinical accuracy: This information is provided for documentation and coding guidance and should not replace professional medical judgment.
Coding standard: ICD-10-CM, current FY guidelines.